ClearPoint Neuro: From Validation To Scale
Source: SeekingAlpha
2026-01-27 04:47:03 ET
ClearPoint's ( CLPT ) preliminary fourth-quarter results were solid, indicating a broad-based reacceleration in its business. This has been supported by the recent acquisition of IRRAS, which appears set to maintain strong growth in the near term. There is also the PRISM 1.5T system clearance and the launch of ClearPoint's preclinical CRO facility. While the status of uniQure's ( QURE ) AMT-130 remains up in the air, a number of other partner programs continue to progress....
Read the full article on Seeking Alpha
For further details see:
ClearPoint Neuro: From Validation To Scale
ClearPoint Neuro, Inc.
NASDAQ: CLPT
CLPT Trading
-1.42% G/L:
$12.87 Last:
507,151 Volume:
$13.91 Open:
CLPT Latest News
January 22, 2026 04:30:00 pm
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
January 12, 2026 08:30:00 am
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
CLPT Stock Data
$387,978,154
26,442,203
2.19%
36
N/A
Medical Equipment & Supplies
Healthcare
US
Solana Beach
